FDA hands Crestor a fighting chance

In the battle of the cholesterol meds, Crestor just got a new weapon. The FDA approved AstraZeneca's application to market the drug not just for lowering cholesterol, but to treat hardening of the arteries, too. It's the first statin to win approval for that indication.

It's an important coup for AstraZeneca, which has been looking for an edge for Crestor--a late entry onto the statin field. As you know, those efforts were compromised earlier this week by research showing the drug didn't alleviate heart failure. And last week, AstraZeneca announced it was facing a generic challenge to Crestor's patents.

- check out the release from AstraZeneca
- read the report from The Times

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.